Sign Out
Kivexa is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and adolescents and children weighing at least 25 kg (see Precautions and Pharmacology: Pharmacodynamics under Actions).
Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin (see Warnings). Abacavir should not be used in patients known to carry the HLA-B*5701 allele.
